List view / Grid view
In this Q&A, Simon Lovestone, Vice President, Global Head, Neuroscience Discovery and Translational Science at Johnson & Johnson, shares how they are leveraging the A/T/N biomarker framework to achieve breakthroughs in Alzheimer’s disease research, in an aim to alter disease progression before daily life is significantly affected.
Enosi Life Science researchers Sir Marc Feldmann, Dr H Michael Shepard and Dr Fiona McCann explain why anti-TNF therapies may be effective in treating COVID-19 associated cytokine storms and other inflammatory conditions.
A new AI project marks the first time 10 pharmaceutical companies have agreed to share data to aid drug discovery.
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
This research group is seeking the potential to unravel novel methods to remove bacterial biofilms from oral surfaces. Oral biofilms consist of a large variety of microorganisms embedded in a complex and robust extracellular matrix...
23 June 2016 | By SMi Group
SMi’s 11th annual Cold Chain Distribution returns to London in December 2016 featuring case study presentations with leading experts...
21 October 2015 | By Kate Douetil
This innovative new global investment fund has gained support from a wide variety of investors, including the UK Government’s Department of Health (DoH), Alzheimer’s Research UK and world-leading major pharmaceutical companies Biogen, GlaxoSmithKline, Johnson & Johnson, Lilly, Pfizer and Takeda...
30 April 2014 | By Johnson & Johnson
Johnson & Johnson announced that its affiliate Janssen Pharmaceutica NV has entered into a novel collaboration with the Stichting International Dispensary Association...
